These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36860656)

  • 1. Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
    Groeneveldt C; van Ginkel JQ; Kinderman P; Sluijter M; Griffioen L; Labrie C; van den Wollenberg DJM; Hoeben RC; van der Burg SH; Ten Dijke P; Hawinkels LJAC; van Hall T; van Montfoort N
    Cancer Res Commun; 2023 Feb; 3(2):325-337. PubMed ID: 36860656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
    Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models.
    Sandker GGW; Middelburg J; Wilbrink E; Molkenboer-Kuenen J; Aarntzen E; van Hall T; Heskamp S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
    Groeneveldt C; Kinderman P; Griffioen L; Rensing O; Labrie C; van den Wollenberg DJM; Hoeben RC; Coffey M; Loghmani H; Verdegaal EME; Welters MJP; van der Burg SH; van Hall T; van Montfoort N
    Cancer Immunol Res; 2024 Mar; 12(3):334-349. PubMed ID: 38194598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.
    Groeneveldt C; Kinderman P; van Stigt Thans JJC; Labrie C; Griffioen L; Sluijter M; van den Wollenberg DJM; Hoeben RC; den Haan JMM; van der Burg SH; van Hall T; van Montfoort N
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35853671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
    Jin J; Wang R; Yang J; Hu H; Wang D; Cai L; Fang Z; Dong S; Hu S; Wang Y; Liu B
    Hum Gene Ther; 2022 Jun; 33(11-12):649-663. PubMed ID: 35272497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
    Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
    Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
    Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.
    Benonisson H; Altıntaş I; Sluijter M; Verploegen S; Labrijn AF; Schuurhuis DH; Houtkamp MA; Verbeek JS; Schuurman J; van Hall T
    Mol Cancer Ther; 2019 Feb; 18(2):312-322. PubMed ID: 30381448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
    Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Blockade of GARP:TGF-β1 and PD-1 Increases Infiltration of T Cells and Density of Pericyte-Covered GARP
    Bertrand C; Van Meerbeeck P; de Streel G; Vaherto-Bleeckx N; Benhaddi F; Rouaud L; Noël A; Coulie PG; van Baren N; Lucas S
    Front Immunol; 2021; 12():704050. PubMed ID: 34386010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.
    Middelburg J; Sluijter M; Schaap G; Göynük B; Lloyd K; Ovcinnikovs V; Zom GG; Marijnissen RJ; Groeneveldt C; Griffioen L; Sandker GGW; Heskamp S; van der Burg SH; Arakelian T; Ossendorp F; Arens R; Schuurman J; Kemper K; van Hall T
    Nat Commun; 2024 Jan; 15(1):48. PubMed ID: 38167722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy.
    Qiang L; Hoffman MT; Ali LR; Castillo JI; Kageler L; Temesgen A; Lenehan P; Wang SJ; Bello E; Cardot-Ruffino V; Uribe GA; Yang A; Dougan M; Aguirre AJ; Raghavan S; Pelletier M; Cremasco V; Dougan SK
    Gastroenterology; 2023 Oct; 165(4):874-890.e10. PubMed ID: 37263309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis.
    Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B
    Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.